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.2013.02.Abstract Background: This prospective controlled studywas designed to evaluate the effect of obes-
ity on the plasma level of Plasminogen Activator Inhibitor-1 (PAI-1) and also to evaluate the effect of
CO2 pneumoperitoneum on the plasma level of PAI-1 in patients underwent laparoscopic surgery.
Methods: The study included two groups; ﬁrst group (non obese) included 30 patients with normal aver-
ageBMIunderwent laparoscopic cholecystectomywhile the second group included 30 obese patientswith
BMI> 30 kg/m2 underwent laparoscopic band ligation or fundoplication surgery. Five ml of venous
blood was collected from each patient in the non obese group once before induction of anesthesia while
three venousblood samples (5 ml)were collected fromeachpatient in the obese groupas follows: ﬁrst sam-
ple was taken before induction of anesthesia to compare it with the non obese group, second sample was
taken after 1 h ofCO2 insufﬂations (to know the effect of CO2 insufﬂations on PAI-1 level) and third sam-
ple was taken 1 week after surgery (to know the remaining effect in the postoperative period).
Results: The level of PAI-1 was signiﬁcantly high (5.423 ± 2.5 ng/ml) in the obese patients compared to
non obese patients (1.4 ± 0.641 ng/ml) (P value = 0.001). The level of PAI-1 was signiﬁcantly high after4234010.
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204 A.A.M. Hassanin et al.CO2 insufﬂations compared to baseline level (6.396 ± 2.542 ng/ml vs. 5.423 ± 2.5 ng/ml) in obese group
(P value = 0.001). And this level also showed signiﬁcant increase up to 1 week (6.01 ± 2.492 ng/ml vs.
5.423 ± 2.5 ng/ml) (P value = 0.028) in the obese group.
Conclusion: The PAI-1 level was higher in obese patients when compared to non obese patients. PAI-1
level was elevated after CO2 insufﬂations and this elevation did not reach base line level up to 1 week after
laparoscopic surgery.
ª 2013 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Obesity has been associated with several cardiovascular risk
factors, such dyslipidemia, hypertension, glucose intolerance
and premature atherosclerosis [1].
‘‘PAI-1’’ level was signiﬁcantly elevated in the plasma of
obese individuals and correlates with BMI. These circulating
levels of PAI-1 are elevated at an early stage of impaired glu-
cose tolerance, resulting in type-2 diabetes and metabolic syn-
drome [2].
An association between an increase in PAI-1 and obesity
has been described. And the decrease in BMI in morbid obesity
shows a favorable effect on the ﬁbrinolytic system due to a de-
crease in PAI-1 levels [3].
The connection between obesity and disordered haemosta-
sis is well established. There is a strong link between inhibition
of ﬁbrinolysis in obese patients and the elevation of PAI-1 [4].
The regulation of ﬁbrinolysis depends on the interaction of
plasma ﬁbrinolytic and anti-ﬁbrinolytic proteins. Fibrinolysis
depends on the enzymatic conversion of plasminogen to plas-
min. This process is mediated by tissue-type and urokinase-type
plasminogen activators. Plasma antiﬁbrinolytic activity is pri-
marily regulated by plasminogen-activator inhibitors (PAIs).
PAI-1 is a single chain glycoprotein that contains from 379 to
381 amino acids. Endothelial and vascular smooth muscle cells
are presumably the main sources of PAI-1 but other cells, such
as platelets, hepatocytes, mesangial cells, ﬁbroblasts, mono-
cytes, macrophages, adipocytes, and stromal cells permeating
the adipose tissue, have also been shown to secrete PAI-1 [5].
On the other hand, it is generally believed that laparoscopic
surgery inﬂicts fewer traumas than open surgery. Many studies
showed that the rise in peritoneal PAI-1 concentration during
laparoscopy suggests an adverse effect of CO2 insufﬂations [6].
The mesothelium cells exposed to ﬂowing CO2 released
more PAI-1 than those exposed to pressurized CO2 and this
may be due to the combined effect of an increased expression
of PAI-1 by CO2 and a longer duration of active PAI-1
through acidosis suggests an adverse effect of the establish-
ment and maintenance of pneumoperitoneum with CO2 and
these might provide a mechanism for peritoneal injury follow-
ing laparoscopic surgery [7].
The aim of this study was to evaluate the effect of obesity
on the level of PAI-1 and the effect of pneumoperitoneum
due to CO2 insufﬂations on the level of PAI-1.2. Methods
This prospective controlled study was conducted after ap-
proval of the local ethics committee of El-Minia University
Hospital, during the period from (May 2011) to (May 2012).A written informed consent was taken for every patient prior
inclusion into the study.
The study included (60) patients. They were classiﬁed into
two groups: ﬁrst group (non obese) included (30) patients with
normal average BMI underwent laparoscopic cholecystec-
tomy. While the second group included (30) obese patients
with BMI > 30 kg/m2 according to the ‘‘WHO’’ classiﬁcation
system [8] underwent laparoscopic band ligation or fundopli-
cation surgery. Five ml of blood was collected from each pa-
tient in the non obese group once before induction of
anesthesia; Three venous blood samples were collected from
the obese group as follows: ﬁrst sample was taken before
induction of anesthesia to compare it with the non-obese
group, second sample was taken after 1 h of CO2 insufﬂations
and third sample was taken 1 week after surgery to measure
the level of PAI-1.
We included, male and female patients, age range between
18 and 60 years old.
We excluded patients with severe medical diseases e.g. car-
diovascular, pulmonary, hepatic and renal diseases.
After taking consent venous blood samples were collected
to measure plasma level of PAI-1 as the following: ﬁrst sample
was taken before induction of anesthesia from the two groups
(this sample was taken to compare between obese and non ob-
ese patient to show the effect of obesity on the plasma level of
PAI-1 and it was considered the baseline value for each patient
in the obese group), second sample was taken 1 h after CO2
insufﬂations from the obese group (this sample was taken to
know the effect of CO2 insufﬂations on PAI-1 level) and the
third sample was taken 1 week after surgery from the obese
group (this sample was taken to know the remaining effect
in the postoperative period).
Five ml of venous blood was collected in citrated tube then
centrifuging the sample at speed 3000 rpm/min. The supernat-
ed was separated, assayed using kits supplied from Clinilab
Company using enzyme immunosorbent technique with refer-
ence range from 0.031 to 2 ng/ml.
In the operating room standard monitors were connected
before and after induction of anesthesia including ECG, pulse
oximeter, capnography and non-invasive blood pressure.
Intravenous line was inserted and the ﬁrst sample was taken
in the two groups. Induction of anesthesia was done by IV fen-
tanyl (1.5–2 lg/kg IV), propofol (1.5–2 mg IV), rocuronium
bromide (0.6 mg/kg) IV followed by intubation. Maintenance
of anesthesia was achieved by sevoﬂurane 2–3% with 100%
oxygen, and fentanyl infusion (1–2 lg/kg/h) allowing a range
of decrease in the hemodynamic parameters within 20% of
the baseline values. During surgery, a CO2 insufﬂator (used
for laparoscopic surgery) was connected to the patient. To
investigate the effect of pressurized CO2 on the PAI-1 level,
a constant pressure of gas around (12–15 mm Hg) was









5.423 ± 2.5 1.4 ± 0.641 0.001
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ﬂations, the second sample was taken in the obese group. At
the end of surgery, all anesthetic medications were stopped
and the residual effect of muscle relaxant was reversed with
neostigmine in a dose of (0.04 mg/kg) and atropine (0.4 mg
per 1 mg neostigmine). After tracheal extubation, all patients
were transferred to recovery room for monitoring of heart
rate, blood pressure and oxygen saturation for 2 h then pa-
tients were transferred to the ward after complete recovery.
The third sample was taken after 1 week.
2.1. Statistical analysis
Statistical analysis was conducted by using ‘‘SPSS’’ release 17
(Chicago, Illinois, USA). Descriptive statistics (mean, standard
deviation ‘‘SD’’) were calculated. Comparative statistics be-
tween the two groups were applied. Unpaired t-test was used
to compare the mean values between the two groups, while
paired t-test was used to compare the mean values in the same
group. Chi-square test was used to compare the difference of
sex distribution between both groups. Signiﬁcant result was
considered when P value was less than (0.05).
3. Results
Total number of (60) patients were recruited for this study (30
patients in each group). There were no signiﬁcant differences
between the two groups as regard the age, sex distribution
and the height. While; the body weight, BMI and duration
of pneumoperitoneum showed signiﬁcant differences between
the two groups (P= 0.001) (Table 1).
The level of PAI-1 was signiﬁcantly high (5.423 ± 2.5 ng/
ml) in the obese patients compared to the normal average
BMI patients (1.4 ± 0.641 ng/ml) (P= 0.001) (Table 2).
The level of PAI-1 was signiﬁcantly high after CO2 insufﬂa-
tions compared to baseline level (6.396 ± 2.542 ng/ml vs.
5.423 ± 2.5 ng/ml) in the obese group (P value = 0.001) and
this level also showed signiﬁcant increase up to 1 week after
surgery compared to the baseline preoperative values
(6.01 ± 2.492 ng/ml vs. 5.423 ± 2.5 ng/ml) (P value = 0.028)
in the obese group (Table 3).
4. Discussion
In our study PAI-1 showed signiﬁcantly high level in the obese
patients when compared to the normal average body weight
patients.
In agreement with our result McGill et al. has demonstrated
that obese diabetic subjects show threefold elevated plasma
concentrations of PAI-1 to healthy lean subjects [9].Table 1 Patient’s data in both groups.
Obese group (n= 30)
Age (y) 36.857 ± 7.087
Sex (M/F) 11/19
Height (cm) 159.713 ± 4.959
Weight (kg) 111.427 ± 19.453
BMI (kg/m2) 42.997 ± 5.714
Duration of pneumoperitoneum 79.29 ± 15.3Weight loss was associated with decrease in plasma PAI-1
which elevated again if weight was regained [10–13]. The same
effect was achieved by surgical removal of fat [14].
Also our results showed that PAI-1 levels were signiﬁcantly
increased after CO2 pneumoperitoneum. And this level showed
signiﬁcant increase up to 1 week after surgery compared to the
baseline preoperative values.
In agreement with our result Matsuzaki et al. [15] who stud-
ied two groups of patients undergoing laparoscopic surgery
group 1: low (8 mm Hg intraperitoneal pressure) and group
II standard (12 mm Hg intraperitoneal pressure) and they
found that PAI-1 in the 12 mm Hg group was signiﬁcantly
high after 1 h of CO2 pneumoperitoneum than those in the
8 mm Hg group and it was signiﬁcantly increased in both
groups after 2 h of pneumoperitoneum.
Also in agreement with our result Bergstro¨m et al. [16]
showed in their study that there was rise in peritoneal PAI-1
concentration during laparoscopy and they suggested that
the elevation was an adverse effect of CO2 insufﬂations which
might affect peritoneal repair.
Bergstro¨m et al. [7] who exposed mesothelial cells to ﬂowing
CO2 and pressurized CO2 and they found that mesothelial cells
exposed to ﬂowing CO2 released more PAI-1 than those ex-
posed to pressurized CO2 and they said that the combined ef-
fect of an increased expression of PAI-1 by CO2 and a longer
duration of active PAI-1 through acidosis suggests an adverse
effect of the establishment and maintenance of pneumoperito-
neum with CO2 and these might provide a mechanism for per-
itoneal injury, adhesion development, and tumor
dissemination following laparoscopic surgery and they recom-
mended further research for the use of other insufﬂations
gases.
In contrast to our study Brokelman et al. [16] how studied
twelve patients undergoing laparoscopic gastric bypass surgery
for morbid obesity and they take biopsies of the peritoneum at
the start of procedure and each 45 min and they concluded
that the level of PAI-1 was not affected throughout the proce-
dure but the activity of tissue plasminogen activator decreased
during the procedure reaching signiﬁcant levels after 90 min of
surgery.Non obese group (n= 30) P value
34.791 ± 8.196 0.306
10/20 0.897
162.350 ± 6.5845 0.085
68.250 ± 10.547 0.001
23.145 ± 2.145 0.001
45.78 ± 20.92 0.001





Sample 1 (before anesthesia) 5.423 ± 2.5
Sample 2 (after pneumoperitoneum) 6.396 ± 2.542 0.001
Sample 3 (after 1 week) 6.01 ± 2.492 0.028
206 A.A.M. Hassanin et al.In conclusion, A PAI-1 level was elevated in obese pa-
tients compared to normal average patients. PAI-1 levels
were elevated after CO2 pneumoperitonium and this elevation
did not reach the base line levels up to 1 week after surgery.
However, further studies are needed to support these results
and to evaluate the role of PAI-1 as a risk factor for the
hypercoagulability state and how to eliminate this risk espe-
cially during the perioperative period and to do a correlation
between the level of PAI-1 in relation to the duration of
pneumoperitonium especially in prolonged laparoscopic
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